- Home
- CCEL vs ESLA Comparison
CCEL vs ESLA Comparison
Compare CCEL & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCEL
- ESLA
- Stock Information
- Founded
- CCEL 1989
- ESLA 2021
- Country
- CCEL United States
- ESLA United States
- Employees
- CCEL N/A
- ESLA N/A
- Industry
- CCEL Managed Health Care
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CCEL Health Care
- ESLA Health Care
- Exchange
- CCEL Nasdaq
- ESLA Nasdaq
- Market Cap
- CCEL 39.9M
- ESLA 35.5M
- IPO Year
- CCEL 1997
- ESLA N/A
- Fundamental
- Price
- CCEL $4.81
- ESLA $0.85
- Analyst Decision
- CCEL Strong Buy
- ESLA Strong Buy
- Analyst Count
- CCEL 1
- ESLA 1
- Target Price
- CCEL $8.50
- ESLA $16.00
- AVG Volume (30 Days)
- CCEL 14.5K
- ESLA 15.8K
- Earning Date
- CCEL 07-15-2025
- ESLA 08-20-2025
- Dividend Yield
- CCEL 12.42%
- ESLA N/A
- EPS Growth
- CCEL N/A
- ESLA N/A
- EPS
- CCEL N/A
- ESLA N/A
- Revenue
- CCEL $31,988,783.00
- ESLA N/A
- Revenue This Year
- CCEL $2.49
- ESLA $101.09
- Revenue Next Year
- CCEL $0.95
- ESLA N/A
- P/E Ratio
- CCEL N/A
- ESLA N/A
- Revenue Growth
- CCEL 1.10
- ESLA N/A
- 52 Week Low
- CCEL $4.68
- ESLA $0.63
- 52 Week High
- CCEL $9.43
- ESLA $3.23
- Technical
- Relative Strength Index (RSI)
- CCEL 43.31
- ESLA 41.00
- Support Level
- CCEL $4.75
- ESLA $0.82
- Resistance Level
- CCEL $5.05
- ESLA $0.88
- Average True Range (ATR)
- CCEL 0.19
- ESLA 0.08
- MACD
- CCEL -0.01
- ESLA -0.00
- Stochastic Oscillator
- CCEL 14.71
- ESLA 27.78
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.